Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Nuvectis Pharma (NVCT), a biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 37th Annual Roth Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvectis Pharma (NVCT), a biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 37th Annual Roth Conference. The event will take place from March 17th-19th in Dana Point, California, where Ron Bentsur, Chairman and Chief Executive Officer, will engage in a fireside chat discussion.
The conference participation highlights Nuvectis's continued engagement with the investment community and its focus on developing innovative treatments for serious unmet medical needs in cancer therapy.
Details
News Market Reaction – NVCT
The recorded move for NVCT in the trading session of this news was +5.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California.
| Event | 37th Annual Roth Conference |
| Date | March 17, 2025 |
| Time | 2:30 PM Pacific Time |
| Link | https://event.summitcast.com/view/YsA9Ty4sRyad4m3F6KNZ7x/PL5B4myr3WCu9J7XMPKBt7 |
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Nuvectis Pharma Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.